December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectis S.A. - American Depositary Shares (NQ:CLLS)

2.210 +0.360 (+19.46%)
Streaming Delayed Price Updated: 2:47 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectis S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
From Cellectis Inc.
Via GlobeNewswire
Earnings Scheduled For May 12, 2025
Via Benzinga
Cellectis Reports Financial Results for the First Quarter 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report First Quarter Financial Results on May 12, 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal
Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones. 
Via MarketBeat
The market is filled with gapping stocks in Friday's session.
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
From Cellectis Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2025
Via Benzinga
Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
From Cellectis Inc.
Via GlobeNewswire
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
From Cellectis Inc.
Via GlobeNewswire
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
From Cellectis Inc.
Via GlobeNewswire
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
From Cellectis Inc.
Via GlobeNewswire
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
From Cellectis Inc.
Via GlobeNewswire
CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q2 2024
CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Cellectis Provides Financial Results for the Second Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment
From Cellectis Inc.
Via GlobeNewswire
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
From Cellectis Inc.
Via GlobeNewswire
Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024
From Cellectis Inc.
Via GlobeNewswire
Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing
From Cellectis Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.